Literature DB >> 3825497

Prognostic indicators in multiple sclerosis.

S Poser, W Poser, G Schlaf, W Firnhaber, K Lauer, M Wolter, P Evers.   

Abstract

The influence of sex, age at onset, course of the disease and initial symptomatology on the mortality of patients with multiple sclerosis is analysed. A sample of 1926 patients was followed up prospectively over 4.9 years. Both, the mortality ratio (number of observed to expected deaths) and the excess death rate are calculated. Whereas the mortality ratio as a parameter of overall mortality is influenced by a variety of factors, such as age and sex; the excess death rate represents the number of extra deaths per 1000 exposed to risk in an indicated year and is, therefore, a parameter of the mortality which is attributed to MS. The excess death rate was comparable for the sexes, it was slightly higher for patients with a higher age at onset and it was clearly higher for the progressive course. Patients with initial diplopia and sensory signs and symptoms had the lowest excess death rate, whereas patients with pareses, cerebral and sphincter disturbances at onset showed the highest excess death rate.

Entities:  

Mesh:

Year:  1986        PMID: 3825497     DOI: 10.1111/j.1600-0404.1986.tb03531.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  4 in total

Review 1.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

2.  Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities.

Authors:  O Olerup; J Hillert; S Fredrikson; T Olsson; S Kam-Hansen; E Möller; B Carlsson; J Wallin
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

3.  Autonomic disorders in multiple sclerosis.

Authors:  E Lensch; W H Jost
Journal:  Autoimmune Dis       Date:  2011-04-17

4.  Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis.

Authors:  C L Hirst; A Pace; T P Pickersgill; R Jones; B N McLean; J P Zajicek; N J Scolding; N P Robertson
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.